<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Adagio Medical Holdings, Inc Common Stock — News on 6ix</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock</link>
<description>Latest news and press releases for Adagio Medical Holdings, Inc Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/adagio-medical-holdings-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835429078dffbe2df0e1558.webp</url>
<title>Adagio Medical Holdings, Inc Common Stock</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock</link>
</image>
<item>
<title>Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-to-participate-in-the-bofa-securities-2026-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-to-participate-in-the-bofa-securities-2026-health-care-conference</guid>
<pubDate>Wed, 29 Apr 2026 12:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., April 29, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, 2026 at 4:35pm PDT in Las Vegas.</description>
</item>
<item>
<title>Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-announces-positive-pivotal-results-for-vclasr-ventricular-ablation-system</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-announces-positive-pivotal-results-for-vclasr-ventricular-ablation-system</guid>
<pubDate>Sun, 26 Apr 2026 13:32:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., April 26, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported six month results from its FULCRUM-VT Investigational Device Exemption ("IDE") clinical trial, which will be used to support the Company’s application for Food and Drug Administration ("FDA") Premarket Approval of the vCLAS Ventricular Ablation System. The results were present</description>
</item>
<item>
<title>Adagio Medical’s ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medicals-ulta-technology-to-be-featured-at-the-heart-rhythm-2026-conference</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medicals-ulta-technology-to-be-featured-at-the-heart-rhythm-2026-conference</guid>
<pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., April 16, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its Ultra-low Temperature Ablation technologies (ULTA) for the treatment of scar-related ventricular tachycardia will be featured in several presentations at the Heart Rhythm Society's 47th Annual Scientific Sessions – Heart Rhythm 2026 conference, to be held from Thursd</description>
</item>
<item>
<title>Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-receives-ide-approval-from-the-fda-to-investigate-next-generation-vclasr-ventricular-ablation-system</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-receives-ide-approval-from-the-fda-to-investigate-next-generation-vclasr-ventricular-ablation-system</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>Designed to Deliver Faster, More Efficient Ablation with Improved Usability on Established, Titratable, Endocardial-Approach ULTA Platform LAGUNA HILLS,</description>
</item>
<item>
<title>Adagio Medical to Participate in the 25th Annual Needham Virtual Conference</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-to-participate-in-the-25th-annual-needham-virtual-conference</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-to-participate-in-the-25th-annual-needham-virtual-conference</guid>
<pubDate>Mon, 06 Apr 2026 12:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., April 06, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be participating at the 25th Annual Needham Virtual Conference being held April 13-16, 2026.</description>
</item>
<item>
<title>Adagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Heart Rhythm Society 2026</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-ultralow-temperature-ablation-us-pivotal-study-results-to-be-presented-in-late-breaking-session-at-heart-rhythm-society-2026</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-ultralow-temperature-ablation-us-pivotal-study-results-to-be-presented-in-late-breaking-session-at-heart-rhythm-society-2026</guid>
<pubDate>Wed, 01 Apr 2026 12:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., April 01, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the pivotal results from the FULCRUM-VT study have been accepted for presentation in a late-breaking clinical science session at Heart Rhythm 2026 (HRS), the annual meeting of the Heart Rhythm Society. This is the first Investigational Device Exemption (IDE) study powere</description>
</item>
<item>
<title>Adagio Medical Reports Fourth Quarter and Full Year 2025 Results</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-reports-fourth-quarter-and-full-year-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-reports-fourth-quarter-and-full-year-2025-results</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation</description>
</item>
<item>
<title>Adagio Medical Announces Publication of Pre-Clinical Results for Next Generation Ventricular Ablation Catheter</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-announces-publication-of-pre-clinical-results-for-next-generation-ventricular-ablation-catheter</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-announces-publication-of-pre-clinical-results-for-next-generation-ventricular-ablation-catheter</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Highlights Improvements in Next Generation ULTA Catheter, Including Potential 50-75% Reduction in Ablation Time LAGUNA HILLS, Calif.--(BUSINESS WIRE)--</description>
</item>
<item>
<title>Adagio Medical Highlights Recent Successful Expanded Access Cases with vCLAS™ System, Including Patients with Premature Ventricular Contractions (PVC)</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-highlights-recent-successful-expanded-access-cases-with-vclastm-system-including-patients-with-premature-ventricular-contractions-pvc</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-highlights-recent-successful-expanded-access-cases-with-vclastm-system-including-patients-with-premature-ventricular-contractions-pvc</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>vCLASTM Used to Treat Patients with No Satisfactory Approved Treatment and/or Failed RF or PFA LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical</description>
</item>
<item>
<title>Adagio Medical to Participate in the 38th Annual Roth Conference</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-to-participate-in-the-38th-annual-roth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-to-participate-in-the-38th-annual-roth-conference</guid>
<pubDate>Wed, 11 Mar 2026 12:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., March 11, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be participating in the 38th Annual Roth Conference on March 23-24, 2026 in Laguna Niguel, CA and will be hosting one-on-one meetings with investors at the conference.</description>
</item>
<item>
<title>Adagio Medical to Participate in the TD Cowen 46th Annual Healthcare Conference</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-to-participate-in-the-td-cowen-46th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-to-participate-in-the-td-cowen-46th-annual-healthcare-conference</guid>
<pubDate>Fri, 20 Feb 2026 13:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., February 20, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at 2:30 PM ET in Boston, MA.</description>
</item>
<item>
<title>New Adagio Medical Publication Highlights Consistent Safety and Effectiveness with Ultralow Temperature Ablation in Broad Range of Patients with Ventricular Tachycardia</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-publication-highlights-consistent-130000368</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-publication-highlights-consistent-130000368</guid>
<pubDate>Wed, 04 Feb 2026 13:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., February 04, 2026--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of results from the U.S. Early Feasibility Study ("EFS") evaluating ultralow temperature cardiac ablation ("ULTC") for the treatment of scar-related ventricular tachycardia ("VT"). The study was published in Circulation: Arrythmia and Electrophysiology.</description>
</item>
<item>
<title>Adagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-participate-btig-13th-130500153</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-participate-btig-13th-130500153</guid>
<pubDate>Mon, 02 Feb 2026 13:05:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., February 02, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be participating at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 10, 2026 in Snowbird, UT.</description>
</item>
<item>
<title>Adagio Medical to Present at the Small Cap Growth Virtual Investor Conference February 5th</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-present-small-cap-133500364</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-present-small-cap-133500364</guid>
<pubDate>Fri, 30 Jan 2026 13:35:00 GMT</pubDate>
<description>Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comLAGUNA HILLS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Adagio Medical Holdings, Inc. (NASDAQ: ADGM), based in Laguna Hills, CA, a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Company management will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestor</description>
</item>
<item>
<title>Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-appoints-two-seasoned-130000234</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-appoints-two-seasoned-130000234</guid>
<pubDate>Mon, 22 Dec 2025 13:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., December 22, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced two key additions to its senior leadership team: Marie-Claude Jacques as Senior Vice President, Global Sales and Antwan Gipson as Senior Vice President, Manufacturing and Operations.</description>
</item>
<item>
<title>Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-appoints-industry-veteran-130000738</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-appoints-industry-veteran-130000738</guid>
<pubDate>Thu, 11 Dec 2025 13:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., December 11, 2025--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company’s Audit Committee and Compensation Committee.</description>
</item>
<item>
<title>Adagio Medical Reports Third Quarter 2025 Results</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-reports-third-quarter-210500091</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-reports-third-quarter-210500091</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., November 12, 2025--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Adagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-present-piper-sandler-130000096</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-present-piper-sandler-130000096</guid>
<pubDate>Wed, 05 Nov 2025 13:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., November 05, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 10:30 a.m. ET at the Lotte Palace in New York, NY.</description>
</item>
<item>
<title>Adagio Medical Closes Financing of $19 Million Upfront; Positions Company to Advance Purpose-Built Technology for Treatment of Ventricular Tachycardia</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-closes-financing-19-120000730</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-closes-financing-19-120000730</guid>
<pubDate>Mon, 20 Oct 2025 12:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., October 20, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the closing of its previously announced private placement (https://investors.adagiomedical.com/news-releases/news-release-details/adagio-medical-announces-pricing-50-million-private-placement), led by existing investors and new healthcare-dedicated institutional investors.</description>
</item>
<item>
<title>Adagio Medical Announces Pricing of up to $50 Million Private Placement of Securities</title>
<link>https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-announces-pricing-50-120000076</link>
<guid isPermaLink="true">https://6ix.com/company/adagio-medical-holdings-inc-common-stock/news/adagio-medical-announces-pricing-50-120000076</guid>
<pubDate>Wed, 15 Oct 2025 12:00:00 GMT</pubDate>
<description>LAGUNA HILLS, Calif., October 15, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or the "Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with certain accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants ("Warrants") that is expected to result in approximately $19 million</description>
</item>
</channel>
</rss>